Today, $MEDBOT-B (02252.HK)$ The stock surged over 22%. As of press time, it was up 22.26%, trading at HKD 25.92 with a turnover of HKD 245 million.
In terms of news, on December 24, MicroPort Surgical Robot-B announced that the UniPathTM Bronchoscopy Robotic Surgery Navigation System (referred to as 'UniPath'), independently developed by its group, had officially received approval from the National Medical Products Administration (NMPA).
The NMPA approval for UniPath marks a milestone breakthrough for the group in leading the technological and application development of the global surgical robotics field. It also signifies that domestic surgical robots have achieved systematic full coverage in minimally invasive diagnostic and treatment key technology pathways. To date, the number of the group's approved and marketed products in the surgical robotics sector has increased to seven, making it the world’s first and currently only company to commercialize products across all five major segments of the surgical robotics market.
According to reports, the newly approved UniPath is a non-invasive natural orifice robotic surgery platform. It features ultra-compliant and ultra-thin snake-like robotic catheters capable of navigating through the body's natural cavities without surface incisions to reach hard-to-access narrow lesion areas. This represents significant progress in the early diagnosis and treatment of early-stage cancers such as small pulmonary nodules.
Editor/KOKO